The SmartTouch for Symbicort is a monitoring device that is installed onto the patient's inhaler to track and improve medication adherence. The Food and Drug Administration (FDA) has granted Adherium ...

Digital respiratory health company Propeller Health has received 510(k) clearance for a sensor and app intended for use with AstraZeneca's Symbicort inhaler for asthma and COPD, the company announced ...

Add Yahoo as a preferred source to see more of our stories on Google. One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially ...

Symbicort contains the active medications budesonide and formoterol. Budesonide belongs to a drug class called corticosteroids. Formoterol belongs to a drug class called long-acting beta2 agonists.

As AstraZeneca fights to defend its aging two-drug inhaler Symbicort against generics, the company has a new approval to bolster its respiratory business. Wednesday, the British drugmaker said the FDA ...

The dosage for Symbicort may vary based on age and diagnosis, but it’s typically two inhalations twice daily. For children ages 6 to 11, the maximum strength is 80/4.5 mcg. For ages 12 and older, a ...

(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...

To earn CME related to this news article, click here. March 5, 2009 — The US Food and Drug Administration (FDA) has approved budesonide plus formoterol fumarate dihydrate inhalation aerosol for the ...

After seeing four of its patents for its Symbicort tossed aside, AstraZeneca has gained a key victory in defense of its blockbuster inhaler. A federal court in West Virginia upheld the company’s claim ...

Please provide your email address to receive an email when new articles are posted on . Two doses of budesonide/glycopyrrolate/formoterol fumarate improved lung ...

AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.